Durham, NCNCT07224334Now EnrollingIRB Ready

Diabetes (DM) Clinical Trial in Durham, NC

Access cutting-edge diabetes (dm) treatment through this phase 1 clinical trial at a research site in Durham. Study-provided care at no cost to qualified participants.

Sponsored by David D'Alessio, M.D.

Quick Self-Assessment

See if you qualify for this Durham location

Preparing your pre-screening questions…

Expert Care in Durham

Access diabetes (dm) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related diabetes (dm) treatment provided free

Apply for This Durham Location

Check if you qualify for this diabetes (dm) clinical trial in Durham, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Durham

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Durham site if eligible
  4. 4Begin participation

About This Diabetes (DM) Study in Durham

Glucagon secretion from α-cells has long been viewed as primarily a counterregulatory mechanism - e.g. an agent with a role to prevent blood sugar from decreasing to levels that compromise function. Our group, along with other researchers, have begun to identify a much more complex role for α-cells, raising questions about when and how glucagon may influence blood glucose levels. This proposal looks to detail proglucagon peptide secretion from α-cells and the impact this has on β-cell function and glucose tolerance, in preclinical studies of human islets and translational studies in human subjects. This protocol registration describes Aim 2 from this NIH grant which involves 2 study populations and separate protocols but addresses a common question. Aim 3 in the grant is focused on a separate hypothesis and will be conducted and published separately from Aim 2.

Sponsor: David D'Alessio, M.D.

Who Can Participate

Inclusion Criteria

Body Mass Index (BMI) \< 27.0
Fasting plasma glucose of ≤ 95 mg/dL or HbA1c value ≤ 5.8% as measured at screening visit

Exclusion Criteria

Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders
Personal history of diabetes or pancreatitis
Personal history of cardiac, gastrointestinal, renal or liver disease
Immediate family history of diabetes
Renal insufficiency (eGFR \< 60 mL/kg/min)
Anemia (hematocrit \< 34%) as measured at screening visit
Pregnant females
Poor vein access
Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)
Apparent sensitivity to the study peptide as determined by the skin test Aim 2B: Inclusion Criteria:
Body Mass Index (BMI) ≥ 27.0
Fasting plasma glucose of \< 126 mg/dL or HbA1c value \< 6.5% as measured at screening visit Exclusion Criteria:
Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders
Personal history of diabetes or pancreatitis
Personal history of cardiac, gastrointestinal, renal or liver disease
Immediate family history of diabetes
Renal insufficiency (eGFR \< 60 mL/kg/min)
AST and/or ALT levels \> 3x the upper limit of the normal range
Anemia (hematocrit \< 34%) as measured at screening visit
Pregnant females
Poor vein access
Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)
Apparent sensitivity to the study peptide as determined by the skin test

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Durham?

Yes, this clinical trial (NCT07224334) has an active research site in Durham, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Diabetes (DM) Treatment Options in Durham, NC

If you're searching for diabetes (dm) treatment options in Durham, NC, this clinical trial (NCT07224334) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Durham research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced diabetes (dm) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all diabetes (dm) clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Durham, NC

See all essential tremor clinical trials recruiting in Durham — not just this study.

Browse Essential Tremor Trials in Durham →

Browse More Trials by Condition

Ready to Join in Durham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Durham, NC